Gilead Sciences (United States)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (United States), United States, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
55%
Total
Publications
5.6K
Total Open
Publications
3.1K
Total
Citations
252K
Open Access
Percentage
55%
Total
Publications
5.6K
Total Open
Publications
3.1K
Total
Citations
252K
Breakdown
Publisher Open
21%
Both
25%
Other Platform Open
8%
Closed
46%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 39%
972
Hybrid 29%
733
No Guarantees 32%
806
Other Platform Open
Domain 80%
1.5K
Institution 22%
404
Other Internet 18%
336
Public 3%
57
Preprint 0%
6
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 1.5K |
DOI | Other Internet | 257 |
Unknown Repository | Other Internet | 90 |
Europe PMC | Domain | 62 |
Figshare | Public | 53 |
DANS - Data Archiving and Networked Services | Institution | 35 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 31 |
University of Modena and Reggio Emilia - IRIS UNIMORE | Institution | 25 |
Elsevier - Scopus | Institution | 20 |
DASH - Digital Access to Scholarship at Harvard | Institution | 19 |